Cloverleaf Bio reported raising $14.8 Million in an initial SEC Form D filing, from an offering of $29.6 Million
Amount Raised
$14.8 Million
Round Type
Seed
New HavenBiotechnologyHealth CareMedicalTherapeuticsInvestors
Description
Cloverleaf Bio has successfully closed a $33 million Seed financing round to support the development of its RNA-based cancer therapies. The round was led by 4BIO Capital and included significant investments from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund. These funds will help advance two lead programs targeting hepatocellular carcinoma and colorectal cancer. The strong participation from pharmaceutical investors underscores interest in Cloverleaf's scientific platform.
Quick answer
Cloverleaf Bio raised $14.8 Million in a Seed round, dated September 8, 2026. Investors: Eli Lilly And Company, AbbVie Ventures, Mission BioCapital, American Cancer Society BrightEdge, 4BIO Capital, Boehringer Ingelheim Venture Fund and Draper Associates. Cloverleaf Bio is based in New Haven, Connecticut, United States.
- How much did Cloverleaf Bio raise?
- Cloverleaf Bio raised $14.8 Million in a Seed round on September 8, 2026.
- Who invested in Cloverleaf Bio?
- Eli Lilly And Company, AbbVie Ventures, Mission BioCapital, American Cancer Society BrightEdge, 4BIO Capital, Boehringer Ingelheim Venture Fund and Draper Associates are named as investors in this round.
- What does Cloverleaf Bio do?
- Cloverleaf Bio is an RNA therapeutics company focused on developing a new class of engineered transfer RNA (tRNA) based payloads for cancer treatment.
- Where is Cloverleaf Bio based and how big is it?
- Cloverleaf Bio is based in New Haven, Connecticut, United States. Fundz records about 4 employees.
- Who are the decision-makers at Cloverleaf Bio?
- Fundz holds 1 contact at Cloverleaf Bio, including the Co-Founder. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Therapeutics around the same time
Companies in the same sectors as Cloverleaf Bio that raised within 45 days of this round, from Fundz verified event records.
- Tivic raised $8.4M (Series B) on October 8, 2026.
- Rouge Therapeutics raised $58M (Series A) on October 6, 2026.
- Omnio raised $3.3M (Seed) on October 2, 2026.
- AvenCell Therapeutics raised $47M (Series C) on September 27, 2026.
- Aqua Medical raised an undisclosed amount (Series B) on September 23, 2026.
- Novadip Biosciences raised $12M (Convertible Note) on September 21, 2026.
Who to call at Cloverleaf Bio, and when
A new round usually means Cloverleaf Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cloverleaf Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cloverleaf Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cloverleaf Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cloverleaf Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cloverleaf Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.